“Diabesity” has become a major global health challenge. 1 It reflects the close pathobiological interplay between obesity and type 2 diabetes, necessitating simultaneous management of both conditions for optimal clinical outcomes. A glycemia-centric approach alone can worsen obesity, especially when weight-gaining therapies are used. Rational management of diabesity prioritizes antidiabetic agents that promote weight reduction.
Semaglutide has shown meaningful reductions in body weight, HbA1c, and insulin requirements, with a favorable safety profile. 2 Join us for an impactful clinical webinar on 19th December 2025 at 8.00 PM IST , where experts will unpack the growing dual burden of diabetes and obesity in everyday practice. This session will highlight emerging real-world strategies for managing diabesity with a more targeted, mechanism-driven approach. Our distinguished panel will…
